Activation of hepatic stellate cells reportedly contributes to progression of hepatocellular carcinoma (HCC). Herein, we use quantitative proteomics and ingenuity pathway analysis to show that transglutaminase 2 (TGM2) is upregulated in the course of activated hepatic stellate cells promoting epithelial-mesenchymal transition (EMT) in HCC-derived cells both in vivo and in vitro. Mechanistically, activated hepatic stellate cells promote TGM2 upregulation in HCC cells through inflammatory signalling; and TGM2-induced depletion of von Hippel-Lindau (VHL) protein, a key molecule in the degradation of hypoxia inducible factor-1a (HIF-1a) under normoxia, then causes HIF-1a to accumulate, thereby producing a pseudohypoxic state that promotes EMT in HCC cells. These findings suggest that the promotion of EMT in HCC cells by activated hepatic stellate cells is mediated by pseudohypoxia induced via TGM2/VHL/HIF-1a pathway. injection of HCC cells and hepatic stellate cells into nude mice. Haematoxylin and eosin (HE)-stained images and immunostaining of E-cadherin and Vimentin are shown (scale bar, 50 μm). Experiments were repeated at least three times in triplicate COMMUNICATIONS BIOLOGY |
H epatocellular carcinoma (HCC) is the fifth most common tumour worldwide and the second most common cause of cancer-related deaths 1 . As critical elements of the HCC microenvironment, activated hepatic stellate cells play central roles in chronic inflammation and subsequent reactive hepatic desmoplasia. Recently they have been found to stimulate growth, migration, and invasion of HCC cells, as several published studies indicate [2] [3] [4] . However, crosstalk between HCC cells and hepatic stellate cells pertaining to hepatic stellate cells activation and the promoting of HCC progression is still poorly understood.
The epithelial-mesenchymal transition (EMT), wherein epithelial cells depolarise, lose their cell-cell contacts, and acquire elongate, fibroblast-like morphology, is a potential mechanism by which tumour cells develop metastatic properties 5 . Functional implications of EMT include enhanced mobility, invasion, and resistance to apoptotic stimuli 5, 6 . Although it has been noted that molecules secreted by hepatic stellate cells promote EMT in HCC cells, enabling migration and invasion, most studies have focused solely on singular hepatic stellate cell-secreted proteins and their roles in this regard; whereas few have investigated key molecules and pathways therein, using whole protein analysis of HCC cells once stimulated by hepatic stellate cells. The latter may reveal a global mechanism of malignant biologic behaviour in HCC, generating more desirable targets of anti-tumour therapy.
Mass spectrometry-based proteomics is a revolutionary technology allowing rapid identification and accurate quantification of thousands of proteins within a complex biological specimen 7 . Comparative proteomic analysis may thus provide an overview of dynamic changes promoted in HCC cells by hepatic stellate cells. Bioinformatics analysis of known and predicted protein-protein interactions can be used to cluster functional data and further characterise roles of differentially expressed proteins.
Transglutaminase 2 (TGM2) belongs to the family of transglutaminase enzymes and is a calcium-dependent cross-linking enzyme that catalyses protein modifications via transamidation, facilitating the formation of lysine combinations or polyaminated proteins in the presence of calcium 8 . TGM2 has been implicated in various biological functions, including differentiation of cells, extracellular matrix (ECM) stabilisation, and cell migration 8 . Recent studies have confirmed that TGM2 induces EMT and thus may contribute to acquired drug resistance in colon, breast, and gastric cancer cells; and increased expression of TGM2 appears to drive glycolytic metabolism in cells of breast and renal cancers [9] [10] [11] [12] [13] .
Findings of the present study confirm the phenomenon wherein activated hepatic stellate cells promote EMT in HCC cells both in vivo and in vitro. Through quantitative proteomics and ingenuity pathway analysis (IPA), we have shown that TGM2 is clearly upregulated as a result, leading to a pseudohypoxic state. This pseudohypoxia is due to enhanced hypoxia inducible factor-1a (HIF-1a) stability under normoxic conditions 14 and TGM2induced depletion of von Hippel-Lindau (VHL) protein, a key molecule in the degradation of HIF-1α 15 . This is the first evidence to our knowledge that promotion of EMT in HCC cells by activated hepatic stellate cells is mediated by pseudohypoxia induced via TGM2/HIF-1a pathway, demonstrating that TGM2 is a therapeutic target linked to inflammatory effects and the pseudohypoxic microenvironment of HCC.
Results
Activated hepatic stellate cells promote HCC cells EMT. We optimised a co-culture system for in vitro use in this study, providing a physiologic milieu for interaction between HCC cells and activated hepatic stellate cells. Compared with control HCC cells, those co-cultured with an activated hepatic stellate cell line morphed into more spindle-like mesenchymal shapes, losing epithelial hallmarks of HCC cells ( Fig. 1a ). They also exhibited greater invasion and resistance to cisplatin (Fig. 1b, c) , expressing less E-cadherin and more vimentin in support of a mesenchymal phenotype and expressing more EMT transcriptional factor Snail and Zeb1 ( Fig. 1d and Supplementary Fig. 1 ) 5 . Upon subcutaneous injection of HCC cells alone or with hepatic stellate cells into nude mice, the HCC cells co-inoculated with hepatic stellate cells (vs. HCC cells alone) were associated with reduced Ecadherin expression and increased vimentin expression in vivo ( Fig. 1e ). Human c-Met expression helps to distinguish HCC cells and hepatic stellate cells, as the HCC cell line MHCC97H is known to highly express c-Met oncogene ( Supplementary Fig. 2 ). These findings indicate that activated hepatic stellate cells promote EMT in HCC cells in vivo and in vitro.
Activated hepatic stellate cells promote TGM2 upregulation in HCC cells. To identify proteins in HCC cells that are implicated in the promotion of EMT by hepatic stellate cells, an integrated approach, consisting of whole-cell protein digestion, stable isotope dimethyl labelling, LC-MS/MS analysis, and database screening was implemented to comparatively profile protein expression in MHCC97H cells, with or without activated hepatic stellate cell line LX2 cells co-culture. In three independent experiments, 106 and 70 proteins were up-or downregulated, respectively, in MHCC97H-Co cells, compared with control MHCC97H cells (Supplementary Tables 1, 2 ). The accuracy of mass spectra results was validated by western blotting of NDRG1, TGM2, and STAT2 ( Supplementary Fig. 3) .
A comprehensive view of the roles played by differentially expressed proteins in EMT was pursued, adopting IPA to group these proteins into functional networks and canonical pathways related to EMT and to determine altered proteins or pathways in MHCC97H cells after co-culture with LX2 cells, all reliant upon the underlying biologic evidence from the curated Ingenuity Pathways Knowledge Base. Functional clusters, including proteins involved in migration of cells, invasion of cells, adhesion of tumour cell lines, and EMT, were drawn from the database, and 35 differentially expressed proteins were identified relative to EMT in MHCC97H-Co cells ( Fig. 2a ). In accordance with previous studies and protein expression average ratios, the study was designed to investigate the biologic significance of TGM2 in activated hepatic stellate cells that promote EMT in HCC cells.
As confirmation of proteomic analysis, another five HCC cell line (MHCC97L, LM3, HepG2, Hep3B and Hu-7) and primary activated human hepatic stellate cells, respectively, were subjected to similar treatment. TGM2 was likewise upregulated in HCC cells after co-culture with activated hepatic stellate cells at both mRNA and protein levels ( Fig. 2b, Supplementary Figs. 1, 4 ). The upregulated TGM2 largely assumed an intracytoplasmic location under immunofluorescence ( Fig. 2c ). We also investigated TGM2 expression in subcutaneous tumours after injecting HCC cells alone or in conjunction with hepatic stellate cells into nude mice. Accordingly, HCC cells co-inoculated with hepatic stellate cells (vs. HCC cells injected alone) demonstrated increased TGM2 expression in vivo ( Fig. 2d ).
Altogether, these findings constitute the first evidence to our knowledge that activated hepatic stellate cells promote TGM2 upregulation in HCC cells in vivo and in vitro, implicating TGM2 upregulation as the main driver of EMT in HCC cells.
TGM2 upregulation promotes EMT in HCC cells. The functional involvement of TGM2 upregulation in promoting EMT in HCC cells was subsequently studied by examining lentivirusmediated TGM2 overexpression (OE) and vector controls in Supplementary Fig. 5 ). We subcutaneously injected HCC-TGM2 OE cells, HCC-Mock cells, and parent HCC cells into nude mice. The tumours arising from injected HCC-TGM2 OE cells (vs. inoculated HCC-Mock cells) had a greater mass, accompanied by reduced E-cadherin expression and increased vimentin expression ( Fig. 3d ). These results again implicate TGM2 upregulation as a driver of EMT in HCC cells in vivo and in vitro.
TGM2 knockdown inhibits EMT in HCC cells. In questioning whether TGM2 upregulation is a necessary condition for promotion of EMT in HCC cells by activated hepatic stellate cells, we studied lentivirus-mediated TGM2 knockdown and vector controls in HCC cells (HCC-shTGM2 and HCC-Mock'). HCC-shTGM2 and HCC-Mock' cells were co-cultured with LX2 cells (HCC-shTGM2-Co and HCC-Mock'-Co). Compared with control HCC-Mock'-Co cells, HCC-shTGM2-Co cells exhibited less invasion and resistance to cisplatin in association with increased E-cadherin expression and reduced vimentin expression ( Fig. 4a-c ). As controls, HCC-shTGM2 and HCC-Mock'cells underwent the same analysis. Compared with HCC-Mock' cells, Compared with control injections of HCC-Mock' cells and hepatic stellate cells, the tumours produced by injecting HCC-shTGM2 cells and hepatic stellate cells were marked by significantly lighter weight, showing increased E-cadherin expression and reduced vimentin expression ( Fig. 4d ). Likewise, the tumours produced by injecting HCC-shTGM2 cells alone were significantly lighter and showed increased E-cadherin expression and reduced vimentin expression compared with injections of HCC-Mock' cells alone ( Fig. 4d ). These results together imply that TGM2 knockdown inhibits promotion of EMT in HCC cells by activated hepatic stellate cells in vivo and in vitro.
TGM2 upregulation leads to HIF-1a accumulation under normoxic conditions. Among the differentially expressed proteins identified through quantitative proteomics, several proteins critical in glycolysis (i.e., PGK1, LDHA, and ENOG) have proved to be upregulated in HCC cells after co-culture with activated hepatic stellate cells, despite an apparently normoxic physiologic milieu 16, 17 . We have confirmed the upregulation of these proteins in HCC-Co cells by western blot (Fig. 5a ). To our knowledge, PGK1, LDHA, and ENOG are all downstream proteins of HIF-1a, and under hypoxic conditions, HIF-1a upregulation promotes their expression 16, 17 . We found levels of HIF-1a proteins in HCC-Co cells to be significantly higher than those of control HCC cells, respectively ( Fig. 5a ). To determine whether TGM2 upregulation regulates HIF-1a expression, HIF-1a, PGK1, LDHA, and ENOG expression levels were measured in HCC-TGM2 OE cells, as well as in corresponding control cells. Subsequently, expression levels of HIF-1a and two downstream proteins, LDHA and PGK1, were all increased in HCC-TGM2 OE cells, compared with control HCC-Mock cells ( Fig. 5b ). However, ENOG expression was not significantly increased in HCC cells showing TGM2 upregulation ( Fig. 5b ). HIF-1a expression was also detected in the subcutaneous tumour implants, including those generated by HCC cells alone, HCC cells with hepatic stellate cells, HCC-Mock cells alone, and HCC-TGM2 OE cells alone. Consequently, in tumour implants devoid of necrosis due to ischaemia and hypoxia, HIF-1a expression was higher in tumour cells following combined injection of HCC cells and hepatic stellate cells, compared with injection of HCC cells alone, and higher HIF-1a expression was evident in tumour cells after implanting HCC-TGM2 OE cells alone, compared with implantation of HCC-Mock cells alone. In addition, we observed higher levels of HIF-1a expression at both cytoplasmic and nuclear location in subcutaneously implanted tumour cells of HCC cells and hepatic stellate cells together or HCC-TGM2 OE cells alone, compared with respective control groups (Fig. 5c ). To confirm this phenomenon, HIF-1a expression was assayed in both cytoplasmic and nuclear locations of HCC-TGM2 OE and HCC-Mock cells by western blot. Indeed, expression of HIF-1a was quantitatively elevated in both cytoplasm and nucleus of HCC-TGM2 OE cells, compared with HCC-Mock cells.
To address the mechanism involved in promotion of EMT by HIF-1a under hepatic stellate cells co-culturing conditions, plasmid-mediated HIF-1a knockdown and plasmid controls were undertaken in HCC-Mock', HCC-shTGM2, and HCC-TGM2 OE cells. The outcomes indicated that EMT was clearly weakened in HCC cells with HIF-1a knockdown co-culturing with hepatic stellate cells, the extent of which was similar to of TGM2 knockdown alone or combined, and EMT was also weakened in HCC-TGM2 OE cells with HIF-1a knockdown (Fig. 5e ).
To study the mechanism by which TGM2 induces increases in HIF-1a protein levels, both gene expression and protein stability of HIF-1a were explored. First, there were no significant differences in oxygen concentrations of the media used for HCC cells and hepatic stellate cells co-culturing, compared with HCC cells cultured alone, or in culturing of HCC cells with upregulated TGM2, compared with control HCC cells (Fig. 5f ). In addition, there were no significant differences in HIF-1a gene expression by HCC cells co-cultured with hepatic stellate cells, compared with HCC cells cultured alone or by HCC cells with upregulated TGM2, compared with control HCC cells ( Fig. 5g ). Therefore, TGM2 was believed to affect the stability of HIF-1a protein, key proteins in the HIF-1a degradation pathway, specifically VHL, were assayed in HCC cells showing TGM2 upregulation and control HCC cells by western blot. In HCC cells showing TGM2 upregulation, accumulated hydroxy-HIF-1a increased, whereas accumulated VHL declined, compared with control HCC cells ( Fig. 5h and Supplementary Fig. 6 ). Pertinent research has shown that TGM2 can bind and polymerise VHL, directly depleting VHL through ubiquitination and proteasomal degradation 15 , so immunoprecipitation was performed to confirm the binding of TGM2 and VHL in HCC cells showing TGM2 upregulation (Fig. 5i ).
In summary, TGM2 upregulation results in the accumulation of HIF-1a under normoxic conditions, and it is through this mechanism of hepatic stellate cells activation that EMT is promoted in HCC cells.
TGM2 is upregulated in HCC cells via inflammatory signalling.
The cause of TGM2 upregulation in HCC cells co-cultured with activated hepatic stellate cells was examined. TGM2 upregulation in cells is reportedly linked to inflammatory signals 18 . IL-6 and TGF-β1 are important inflammatory mediators that have been implicated in tumour metastasis and the triggering of EMT, and they have been identified in proteins secreted by activated hepatic stellate cells 10, 19, 20 . According to our observations, levels of IL-6 and TGF-β1 released into the supernatant of our HCC cells and hepatic stellate cells co-culture system were significantly higher than levels associated with HCC cells alone ( Fig. 6a, b ). We also assayed TGM2 in HCC cells after IL-6 and TGF-β1 treatment, discovering that it was upregulated, compared to levels found in control HCC cells ( Fig. 6c, d ). Furthermore, TGM2 knockdown inhibited EMT in HCC cells promoted by IL-6 and TGF-β1 treatment (Fig. 6c, d) .
High TGM2 expression in HCC tissue is associated with poor clinical outcomes. Using tissue microarrays, immunohistochemistry was performed to gaugeTGM2 protein levels in tumour specimens from 149 patients with HCC. In scored samples, 69 were considered high, and the remaining 80 were considered low. After a median follow-up of 47 months (range, 1-64 months), patients with high (vs. low) TGM2 levels displayed significantly worse recurrence-free (P = 0.006) and overall (P = 0.003) survival rates (Fig. 6e ).
In addition, gene expression analysis using The Cancer Genome Atlas (TCGA) database showed that there was no significance between TGM2 mRNA levels in HCC tissues and the adjacent normal tissues, but the TGM2 expression in HCC to adjacent normal tissues ratio was significantly higher in TNM stage II/III in comparison to in stage I patients ( Supplementary  Fig. 7 ). There was a positive correlation between TGM2 and vimentin expression ( Supplementary Fig. 7 , r 2 = 0.276, p < 0.01), but no significant correlation between TGM2 and E-cadherin expression in 371 HCC tissues from TCGA (r 2 = 0.047, p = 0.366). 
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Discussion
Although it has been reported that molecules secreted by hepatic stellate cells promote EMT in HCC cells, unleashing their migratory and invasive potential, the complex crosstalk between HCC cells and hepatic stellate cells is still poorly understood [2] [3] [4] . Most studies have targeted singular proteins secreted by hepatic stellate cells, characterising their roles in the progression of HCC. However, few have investigated the full gamut of protein changes in HCC cells (once stimulated by hepatic stellate cells) to perhaps unearth a global mechanism for their malignant biologic behaviour and better suited targets of anti-tumour therapy.
In the present study, the prominent role of TGM2 in activated hepatic stellate cells promoting EMT of HCC cells, has been demonstrated through quantitative proteomics and IPA and confirmed by in vitro and in vivo experimentation. Additionally, activated hepatic stellate cells seem to promote TGM2 upregulation in HCC cells through inflammatory signals, with TGM2 upregulation causing HIF-1a accumulation under normoxic conditions, and HIF-1a-mediated pseudohypoxia promoting EMT in HCC cells (Fig. 6f ). This newly described chain of events represents a distinctive path through the HCC microenvironment in which inflammatory signals are converted to hypoxic signals by TGM2 upregulation, even under normoxic conditions. Inhibition of TGM2 upregulation thus promises a unique paradigm in HCC treatment, aimed at suppressing tumour progression by a remodelling of tumour milieu.
EMT is an important initiating event in cancer metastasis, stemness, and drug resistance 5, 6 . Studies have shown that TGM2 influences EMT both in cancerous and fibrotic states [9] [10] [11] 21 . Herein, we have shown that TGM2 upregulation promotes EMT in HCC cells, and that TGM2 knockdown inhibits the promotion of EMT by activated hepatic stellate cells in HCC cells, confirming the importance of TGM2 in tumour progression. These findings are aligned with previous studies of colon, breast, and gastric cancer cells, all indicating that TGM2 is pivotal in inducing EMT [9] [10] [11] . Unfortunately, other conclusions reached in terms of the mechanism involved have varied, implicating Wnt/βcatenin, ERK1/2, AKT, and NF-κB pathways. Still, the overriding process is likely to emerge as the endpoint of a high-throughput and integrated strategy. Through our quantitative proteomics approach, we have discovered that a pseudohypoxic state induced in the microcosm of HCC appears to activate hepatic stellate cells and promote EMT, which may then regulate or affect any of the pathways above 22, 23 . It is also curious that HCC cells upregulate HIF-1a by initiating hypoxic responses under conditions of normoxia. Mechanistically, TGM2 consumes VHL, a critical molecule in the degradation of HIF-1a under normoxia 15 , and the resultant falsely hypoxic state is attributable to accumulation of HIF-1a.
The observation that hepatic stellate cells induce upregulation of TGM2, producing high basal expression of HIF-1α, is of immense importance, suggesting a major role for TGM2 in inflammation-regulated cancer progression. Expression of HIF-1α is considered a negative prognostic factor, given its implications in processes including chemoresistance, angiogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism, and genome stability 22, 23 . Because it is unstable under normoxic conditions, the effects HIF-1 are typically consigned to hypoxic disorders only. Our data have demonstrated that in HCC cells, HIF-1α stability is governed by hepatic stellate cells through TGM2 upregulation. There are vast scientific and clinical ramifications attached to such interaction between HCC cells and hepatic stellate cells.
Earlier reports have indicated that HCC cells can also stimulate the activation of hepatic stellate cells 24 . As critical elements of the HCC microenvironment, activated hepatic stellate cells play central roles in chronic inflammation and subsequent reactive hepatic desmoplasia; are known to secrete growth factors and cytokines; and in turn, stimulate the growth, migration, and invasion of HCC cells, according to several recently published studies [2] [3] [4] . Cytokines related to inflammation, such as IL-6 and TGF-β1, have been identified as secreted proteins of activated hepatic stellate cells 20 , also having been implicated in tumour metastasis and the triggering of EMT 10, 19 . Additionally, inflammatory signals have been shown to upregulate TGM2 expression via NF-κB activation in tumour cells 10, 18 . According to our results, activated hepatic stellate cells promote TGM2 upregulation, with ensuing EMT in HCC cells responsible for secretion of cytokines related to inflammation, thus offering a somewhat full depiction of cell-cell interaction in this setting.
TGM2 has been implicated in various biologic functions, including differentiation of cells, ECM stabilization, and cell migration 8 . The clinical significance of TGM2 has been followed with keen interest in recent years. Our efforts have proven that high TGM2 expression in HCC tissue is associated with lower rates of recurrence-free and overall survival. Others have similarly shown that TGM2 expression is a prognostic marker in colon cancer and non-small cell lung cancer; and in proteomic profiles, TGM2 upregulation in HCC correlates with early recurrence [25] [26] [27] .
In summary, the present data show that activated hepatic stellate cells promote EMT in HCC cells, mediated by a pseudohypoxic state that is induced via TGM2/HIF-1a pathway. Furthermore, TGM2 appears to be a central signal linking inflammatory effects and pseudohypoxia in the HCC microenvironment. TGM2 knockdown inhibits HCC cells EMT promoted by activated hepatic stellate cells in vivo and in vitro. a Diminished invasiveness of HCC cells (MHCC97H and HepG2) after lentivirus-mediated TGM2 knockdown co-culturing with LX2 cells (MHCC97H-shTGM2-Co and HepG2-shTGM2-Co), compared with two HCC cell lines and vector control co-cultured with LX2 cells (MHCC97H-Mock'-Co and HepG2-Mock'-Co), respectively (scale bar, 50 μm); b Less resistance to cisplatin in MHCC97H-shTGM2-Co and HepG2-shTGM2-Co cells, compared with MHCC97H-Mock'-Co and HepG2-Mock'-Co cells, respectively (*P < 0.05, mean ± SEM); c Higher E-cadherin and lower Vimentin expression levels in MHCC97H-shTGM2-Co and HepG2-shTGM2-Co cells, compared with MHCC97H-Mock'-Co and HepG2-Mock'-Co cells, respectively (western blotting); and d Subcutaneous tumours following injection of MHCC97H-shTGM2 cells and LX2 cells were lighter compared with counterpart injections of MHCC97H-Mock'cells and LX2 cells (*P < 0.05, **P < 0.01, mean ± SEM). Note higher E-cadherin and lower Vimentin expression levels in tumour cells produced by injecting MHCC97H-shTGM2 cells and LX2 cells into nude mice, compared with counterpart injection of MHCC97H-Mock' and LX2 cells. Images of immunostained TGM2, E-cadherin, and Vimentin are shown (scale bar, 50 μm). Experiments were repeated at least three times in triplicate cells in polystyrene dishes can recapitulate the features of activated hepatic stellate cells and has been widely accepted as an in vitro model for hepatic stellate cells activation studies 7 . All the cell lines passed the conventional tests of cell line quality control methods (e.g., morphology, isoenzymes, mycoplasma). All cell cultures were undertaken in a temperature-controlled (37°C) humidified atmosphere (5% CO 2 ). CTNNB1, P53, and VHL expression were assessed in the 6 HCC cell lines by western blot (Supplementary Fig. 8 ).
Lentivirus, plasmids, and transfection. Lentivirus/GV287-TGM2 OE (Ubi-TGM2-3FLAG-SV40-EGFP), Lentivirus/GV115-shTGM2 (hU6-shTGM2-CMV- 
EGFP)
, and corresponding control lentiviruses (GV287 and GV115, respectively) were purchased (GeneChem, Shanghai, China). TGM2 OE was constructed from full-length TGM2 cDNA, and shTGM2 was generated from shRNA (5′-GCAGTGACTTTGACGTCTT-3′) targeting the TGM2 cDNA sequence. Plasmid/ GV248-shHIF-1a (hU6-shHIF-1a-Ubi-EGFP-IRES-puromycin) and control plasmid/GV248 were also purchased (GeneChem). shRNA (5′-GATGAAAGAATT ACCGAAT -3′) was used to target the HIF-1a cDNA sequence, using a non-target shRNA as control. All transfections were conducted in accord with manufacturersupplied protocols. Oligo sequences are also shown in Table 1 . Transwell migration assay. Cell invasion was assessed using transwell migration assays in conjunction with co-cultured HCC cells 29 . Matrigel (50 μL; BD Biosciences, Franklin Lakes, NJ, USA) diluted in DMEM (1:8) was added to each well 4 h before cells were seeded onto membranes (Boyden chambers; Millipore Sigma). Cells in serum-free DMEM (5 × 10 4 ) were then seeded onto membranes (8.0-μm pore size) in each upper well chamber of a 24-well plate. DMEM containing 10% FBS was added to each lower chamber. After 24 h, cells reaching membrane undersides were stained (Giemsa) and counted at 200x magnification.
CCK-8 assay. Briefly, HCC cell lines were seeded onto a 96-well plate (3 × 10 3 cells/well) 12 h prior to treatment with various concentrations (0-512 μg/ mL) of cisplatin (Sigma-Aldrich, St. Louis, MO, USA) 29 . The cells were grown in a final 100-mL volume of culture medium per well. CCK-8 labelling reagent (10 μL; Dojindo Molecular Technologies Inc, Kumamoto, Japan) was added to each well and incubated for 1 h. Absorbance of the formazan product was measured at 450 nm. To achieve significance in quantitative analysis, experiments were repeated at least three times.
Animal experimentation. All animal experimentation protocols were approved by the Ethical Committee on Animal Experiments of the Animal Care Committee at Fudan University, and all testing complied with guidelines of the Shanghai Medical Experimental Animal Care Commission. Animals were maintained under specific pathogen-free conditions, making all efforts to minimise any suffering. All were purchased (SLAC Laboratory Animal Co Ltd, Shanghai, China), obtaining male BALB/c nu/nu mice (weights, 18-20 g) at 4 weeks of age. Each of 12 mice was injected subcutaneously (upper right flank) with a suspension (5 × 10 6 ) of MHCC97H cells alone (n = 6) or with LX2 cells (5 × 10 6 , 1:1, n = 6). Another 18 mice were similarly injected with suspensions (5 × 10 6 ) of MHCC97H cells (n = 6), MHCC97H-Mock cells (n = 6), or MHCC97H-TGM2 OE cells (n = 6); and the process was repeated in 24 more mice, injecting MHCC97H-Mock' cells alone (5 × 10 6 , n = 6) or with LX2 cells (5 × 10 6 , 1:1, n = 6) and then MHCC97H-shTGM2 cells alone (5 × 10 6 , n = 6) or with LX2 cells (5 × 10 6 , 1:1, n = 6). The experiments were continued for 20 days. Tumour growth kinetics were recorded every 2 days after injection. Animals were sacrificed once the tumours were removed, weighing and fixing the tissue in 10% formalin or freezing specimens in liquid nitrogen.
Preparation of whole-cell lysates, subcellular fractionation, and western blot.
Briefly, whole-cell lysates were extracted using RIPA lysis buffer (Beyotime Biotechnology, Jiangsu, China) plus phenylmethylsulfonyl fluoride (PMSF) and a phosphatase inhibitor (Roche, Basel, Switzerland) at 4°C 30 . Cytosol and nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockford, IL, USA). Protein samples were separated via 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred onto polyvinylidene difluoride membranes (Millipore Sigma). The membranes were blocked in 5% bovine serum albumin (Beyotime Biotechnology) for 2 h, then washed and incubated with primary antibodies, at concentrations specified by the manufacturer, overnight at 4°C. After washing, the membrane was incubated with appropriate HRP-conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) and examined using enhanced chemiluminescence (Pierce Biotechnology). The proteins were quantified by densitometry, using ImageJ software (National Institutes of Health, Bethesda, MD, USA), and normalised to relative internal standards. All experiments were performed in triplicate. A listing of primary antibodies used appears in the Supplementary Table 3 . Original blot images corresponding to immunoblots in the main figures are presented in Supplementary Fig. 9 .
Immunoprecipitation. Briefly, whole-cell lysates were extracted using NP-40 lysis buffer (Beyotime Biotechnology) with phosphatase inhibitor (Roche) at 4°C 31 . Total protein (1 mg) was incubated with TGM2 antibody (2 μg) for 18 h. The complex was then collected using Agarose A/G protein beads (Millipore Sigma) for 4 h and washed in cold PBS buffer containing protease and phosphatase inhibitors.
Immunofluorescence. Expression of TGM2 in HCC cells was determined by immunofluorescence 30 . HCC cells were grown on glass cover slips to 20-30% confluency and then fixed, permeabilized, blocked, and incubated with TGM2 antibody overnight at 4°C. The slides were subsequently washed and incubated with Alexa fluor 555-conjugated secondary antibody (Beyotime Biotechnology). Activated hepatic stellate cells promote TGM2 upregulation in HCC cells through inflammatory signals and heightened TGM2 expression in HCC tissue bodies poorly for clinical outcomes: a, b Levels of IL-6 and TGF-β1 released in supernatant of co-cultured HCC cells and hepatic stellate cells proved significantly higher than levels produced by HCC cells alone (enzyme-linked immunosorbent assay) (*P < 0.05, **P < 0.01, mean ± SEM, experiments were repeated three times in triplicate); c, d TGM2 upregulation in HCC cells after IL-6 treatment (0, 50, and 250 pg/mL) and TGF-β1 treatment (0, 300, and 1500 pg/mL), with TGM2 knockdown inhibiting rise in E-cadherin and fall in Vimentin expression levels promoted in HCC cells by IL-6 and TGF-β1 treatment (*P < 0.05, **P < 0.01, mean ± SEM, experiments were repeated three times in triplicate); e Heightened (vs. low-level) postoperative TGM2 expression linked with significantly worse recurrence-free and overall survival in patients with HCC (scale bar, 50 μm). Log-rank P-values are shown; and f Schematic illustration of EMT promotion in HCC cells by activated hepatic stellate cells through TGM2 upregulation Table 1 Oligo sequences used in this study shRNA shTGM2
5′-GCAGTGACTTTGACGTCTT -3′ Targets TGM2 cDNA sequence Plasmid/GV248-shHIF-1a 5′-GATGAAAGAATTACCGAAT -3′ Targets HIF-1a cDNA sequence qRT-PCR Forward Reverse TGM2
5′-ACCGCTGAGGAGTACGTCTG -3′ 5′-AAAGGCTCCAGGTTGAGGTT -3′ HIF-1a 5′-TGCAACATGGAAGGTATTGC -3′ 5′-GCACCAAGCAGGTCATAGGT -3′ 18S RNA 5′-CAGCCACCCGAGATTGAGCA -3′ 5′-TAGTAGCGACGGGCGGTGTG -3′
